Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9BYB0: Variant p.Pro1654Thr

SH3 and multiple ankyrin repeat domains protein 3
Gene: SHANK3
Feedback?
Variant information Variant position: help 1654 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Proline (P) to Threonine (T) at position 1654 (P1654T, p.Pro1654Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (P) to medium size and polar (T) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help Found in patients with neuropsychiatric disorders; uncertain significance. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 1654 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1731 The length of the canonical sequence.
Location on the sequence: help SRSPSPSPLPSPASGPGPGA P GPRRPFQQKPLQLWSKFDVG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         SRSPSPSPLPSPASGPGPGAPGPRRPFQQKPLQLWSKFDVG

Mouse                         SRSPSPSPLPSPSPGSGPSA-GPRRPFQQKPLQLWSKFDVG

Rat                           SRSPSPSPLPSPSPGSGPSA-GPRRPFQQKPLQLWSKFDVG

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 1731 SH3 and multiple ankyrin repeat domains protein 3
Region 1627 – 1664 Disordered
Compositional bias 1638 – 1658 Pro residues
Modified residue 1634 – 1634 Phosphoserine
Modified residue 1636 – 1636 Phosphoserine
Modified residue 1638 – 1638 Phosphoserine



Literature citations
Contribution of SHANK3 mutations to autism spectrum disorder.
Moessner R.; Marshall C.R.; Sutcliffe J.S.; Skaug J.; Pinto D.; Vincent J.; Zwaigenbaum L.; Fernandez B.; Roberts W.; Szatmari P.; Scherer S.W.;
Am. J. Hum. Genet. 81:1289-1297(2007)
Cited for: VARIANTS ARG-321; LEU-341; SER-970; THR-1173; LEU-1263; VAL-1406; THR-1443; SER-1557 AND THR-1654; INVOLVEMENT IN NEUROPSYCHIATRIC DISORDERS; Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders.
Durand C.M.; Betancur C.; Boeckers T.M.; Bockmann J.; Chaste P.; Fauchereau F.; Nygren G.; Rastam M.; Gillberg I.C.; Anckarsaeter H.; Sponheim E.; Goubran-Botros H.; Delorme R.; Chabane N.; Mouren-Simeoni M.-C.; de Mas P.; Bieth E.; Roge B.; Heron D.; Burglen L.; Gillberg C.; Leboyer M.; Bourgeron T.;
Nat. Genet. 39:25-27(2007)
Cited for: VARIANTS CYS-12; GLY-198; THR-224; CYS-300; GLY-963; VAL-1011; HIS-1231; GLY-1566 AND THR-1654; INVOLVEMENT IN NEUROPSYCHIATRIC DISORDERS; CHARACTERIZATION OF VARIANTS CYS-12 AND CYS-300;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.